Lenvima
Drug
Eisai Inc.
Total Payments
$86.7M
Transactions
128,549
Doctors
17,220
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.0M | 20,899 | 7,710 |
| 2023 | $6.9M | 20,941 | 7,028 |
| 2022 | $8.0M | 20,579 | 6,026 |
| 2021 | $7.7M | 13,192 | 4,061 |
| 2020 | $17.5M | 13,350 | 2,675 |
| 2019 | $19.5M | 18,789 | 3,842 |
| 2018 | $14.0M | 12,147 | 2,611 |
| 2017 | $9.2M | 8,652 | 1,995 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $70.5M | 37,068 | 81.3% |
| Consulting Fee | $7.4M | 2,836 | 8.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.8M | 1,916 | 4.4% |
| Food and Beverage | $2.0M | 81,805 | 2.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1.2M | 528 | 1.3% |
| Travel and Lodging | $926,403 | 3,060 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $861,509 | 339 | 1.0% |
| Grant | $122,000 | 26 | 0.1% |
| Education | $23,122 | 971 | 0.0% |
Payments by Type
Research
$70.5M
37,068 transactions
General
$16.3M
91,481 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Eisai Inc. | $30.9M | 0 |
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | Eisai Inc. | $10.3M | 0 |
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | Eisai Inc. | $4.2M | 0 |
| An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects with Hepatocellular Carcinoma | Eisai Inc. | $3.2M | 0 |
| A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile | Eisai Inc. | $3.1M | 0 |
| A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | Eisai Inc. | $2.5M | 0 |
| A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | Eisai Inc. | $2.0M | 0 |
| An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors | Eisai Inc. | $1.5M | 0 |
| A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment | Eisai Inc. | $1.3M | 0 |
| A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma | Eisai Inc. | $1.3M | 0 |
| A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) who have progressed on prior PD-1/PD-L1 immune checkpoint inhibition | Eisai Inc. | $1.0M | 0 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer | Eisai Inc. | $949,291 | 0 |
| Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers | Eisai Inc. | $754,618 | 0 |
| A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosarcoma (OLIE) | Eisai Inc. | $751,619 | 0 |
| A Multicenter Phase 0 Study In Healthy Subjects and Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma For Assessment In Vitro Lenvatinib Protein Binding | Eisai Inc. | $704,846 | 0 |
| An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | Eisai Inc. | $612,265 | 0 |
| An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment | Eisai Inc. | $403,802 | 0 |
| Immunogenomic Dissection of Renal cell Carcinoma Patients Treated with Lenvatinib in Combination with Pembrolizumab | Eisai Inc. | $357,178 | 0 |
| Presurgical Neoadjuvant Lenvatinib for Locally Invasive Thyroid Cancer | Eisai Inc. | $349,546 | 0 |
| A Phase II Study of Lenvatinib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | Eisai Inc. | $342,297 | 0 |
Top Doctors Receiving Payments for Lenvima — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Gynecologic Oncology | Houston, TX | $35,237 | 21 |
| , MD | Hematology & Oncology | La Jolla, CA | $34,818 | 15 |
| , M.D | Gynecologic Oncology | Grand Rapids, MI | $34,682 | 20 |
| , APRN | Adult Health | Independence, KS | $34,233 | 117 |
| , M.D | Hematology & Oncology | Washington, DC | $34,100 | 27 |
| , MD | Student in an Organized Health Care Education/Training Program | Orange, CA | $33,859 | 32 |
| Bryan Mciver | — | Tampa, FL | $33,204 | 26 |
| , M.D | Diagnostic Radiology | Boston, MA | $32,940 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | Fort Myers, FL | $32,892 | 45 |
| , M.D | Hematology & Oncology | Miami, FL | $32,718 | 44 |
| , CNP | Women's Health | Columbus, OH | $32,388 | 35 |
| , MD | Gynecologic Oncology | Orlando, FL | $32,145 | 29 |
| , M.D | Hematology & Oncology | Fort Worth, TX | $31,704 | 54 |
| , M.D | Medical Oncology | Durham, NC | $31,332 | 18 |
| , MD | Diagnostic Radiology | Stony Brook, NY | $30,860 | 5 |
| , MD | Medical Oncology | Boston, MA | $30,591 | 21 |
| , M.D | Internal Medicine | San Juan, PR | $30,029 | 73 |
| , MD | Obstetrics & Gynecology | Hilliard, OH | $29,826 | 30 |
| , M.D | Hematology | New Orleans, LA | $29,341 | 33 |
| , MD | Gynecologic Oncology | Saint Louis, MO | $29,037 | 23 |
| , MD | Internal Medicine | Wichita, KS | $28,656 | 62 |
| , M.D | Internal Medicine | Cleveland, OH | $28,622 | 24 |
| , MD | Medical Oncology | Palo Alto, CA | $28,108 | 31 |
| , M.D | Gynecologic Oncology | Cincinnati, OH | $27,371 | 9 |
| , M.D | Medical Oncology | Boston, MA | $27,347 | 32 |
Ad
Manufacturing Companies
- Eisai Inc. $81.6M
- EISAI INC. $4.8M
- Eisai Co., Ltd. $325,373
Product Information
- Type Drug
- Total Payments $86.7M
- Total Doctors 17,220
- Transactions 128,549
About Lenvima
Lenvima is a drug associated with $86.7M in payments to 17,220 healthcare providers, recorded across 128,549 transactions in the CMS Open Payments database. The primary manufacturer is Eisai Inc..
Payment data is available from 2017 to 2024. In 2024, $4.0M was paid across 20,899 transactions to 7,710 doctors.
The most common payment nature for Lenvima is "Unspecified" ($70.5M, 81.3% of total).
Lenvima is associated with 20 research studies, including "A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors" ($30.9M).